Clinical trials
Metastatic Castration-resistant Prostate Cancer clinical trials
Below are recruiting metastatic castration-resistant prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 220 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06134232RecruitingPhase 2
Extra sipuleucel-T after Provenge for prostate cancer
This trial tests whether adding one extra infusion of sipuleucel-T (the same drug as Provenge) after the standard three doses can help men with advanced prostate cancer that no longer responds to hormone therapy. It is for men who have already finished their three Provenge infusions and have mild or no symptoms.
Tuscon, ArizonaAges 18 years+ - NCT06031805Recruiting
Real-world study of olaparib for prostate cancer
This study looks at how men with advanced prostate cancer that has spread are doing while taking the drug olaparib. Researchers want to understand how well the drug works and what happens to patients over time.
AmiensAges 18 years+ - NCT05563558RecruitingPhase 2
Testing pembrolizumab plus chemotherapy for aggressive metastatic prostate cancer
This Phase 2 trial tests pembrolizumab together with carboplatin and cabazitaxel in men with aggressive, metastatic prostate cancer that has become resistant to hormone therapy. It may help shrink tumors and improve outcomes for people with hard-to-treat forms of prostate cancer.
MadridAges 18 years+ - NCT05603559RecruitingEarly Phase 1
Study of radioactive PSMA-targeting treatment for advanced prostate cancer
This early-phase study tests a cancer medicine that uses radiation to target prostate cancer cells that carry a specific marker (PSMA). It may help people whose metastatic prostate cancer has stopped responding to hormone therapy and/or chemotherapy.
Beijing, Beijing MunicipalityAges 18–90 - NCT05570994Enrolling by invitationPhase 1/Phase 2
PSMA-targeted radioactive drug for advanced prostate cancer
This Phase 1/2 study tests a radioactive treatment that targets PSMA, a protein often found on prostate cancer cells. It’s for men whose prostate cancer has worsened despite hormone-blocking pills like abiraterone or enzalutamide, aiming to help shrink or control the disease.
Vancouver, British ColumbiaAges 18 years+ - NCT04986423RecruitingPhase 2
Add ZEN003694 to enzalutamide for resistant prostate cancer
This Phase 2 study tests whether adding ZEN003694 to enzalutamide works better than enzalutamide alone in men whose prostate cancer has spread and is no longer controlled by hormone lowering treatments. It focuses on people who either did not respond well to abiraterone (poor responders) or did respond (responders), then compares outcomes between treatment groups.
Los Angeles, CaliforniaAges 18 years+ - NCT04838899Recruiting
Radiation for limited, progressing prostate cancer on abiraterone
This study tests whether a very focused type of radiation (SABR) can control a small number of prostate cancer spots that are starting to grow while you’re already on abiraterone. It may help by treating only the areas that are progressing, while other areas remain controlled.
Toronto, OntarioAges 18 years+ - NCT03851640RecruitingPhase 3
Study drug for advanced prostate cancer that kept spreading despite standard treatments
This Phase 3 study tests HC-1119 soft capsules in men with metastatic castration-resistant prostate cancer—cancer that keeps progressing even when testosterone is blocked. It aims to see whether the drug works better than expected and is safe, especially after prior treatments like abiraterone and/or docetaxel.
ShanghaiAges 18 years+ - NCT03522064RecruitingPhase 2
HRD-positive advanced prostate cancer trial with androgen therapy and chemo
This Phase 2 study tests whether blocking male hormones (androgen therapy) plus the chemotherapy drug carboplatin can shrink advanced prostate cancer in men with specific DNA repair problems. It is for cases where prostate-specific antigen (PSA) is rising even though testosterone is already kept very low.
Sydney, New South WalesAges 18 years+ - NCT03903835RecruitingPhase 3
Biomarker-guided treatment for metastatic prostate cancer
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
AalstAges 18 years+ - NCT06217822RecruitingPhase 1
Testing a new radiation therapy for advanced prostate cancer
This trial tests a new radioactive drug, 225Ac-PSMA-Trillium, that targets prostate cancer cells. It is for people whose advanced prostate cancer has stopped responding to hormone therapy and may have spread.
Duarte, CaliforniaAges 18 years+ - NCT07660211RecruitingPhase 1
Radioactive treatment for advanced prostate cancer
This trial tests a radioactive treatment (177Lu-PSMA-VG01) that targets a protein called PSMA on prostate cancer cells. It's for men whose cancer has spread and hasn't gotten better with other treatments.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06529549Recruiting
Organoid drug test for advanced prostate cancer
This trial uses a lab test on a tiny sample of your tumor (called an organoid) to find which drug might work best for your advanced prostate cancer. It's for men whose cancer has stopped responding to hormone therapy and got worse after first treatment.
Guangzhou, GuangdongAges 18–75 - NCT06480110RecruitingPhase 1/Phase 2
Ebastine plus docetaxel for advanced prostate cancer
This trial tests if combining the allergy drug ebastine with the chemotherapy docetaxel can help men with advanced prostate cancer that has stopped responding to hormone therapy. It may offer a new treatment option for those whose cancer is still growing.
CopenhagenAges 18 years+ - NCT06401980RecruitingPhase 2
Darolutamide for advanced prostate cancer that has stopped responding to hormone therapy
This trial tests the drug darolutamide for men whose prostate cancer has spread and is no longer controlled by standard hormone therapy. It may be an option if you've already had certain hormone treatments for at least 12 months but your cancer is still progressing.
AarauAges 18 years+ - NCT06866938RecruitingPhase 2
Second course of PSMA-targeted radiation for prostate cancer
This study tests giving the targeted radiation drug [177Lu]Lu-PSMA again to men whose prostate cancer has started growing after an earlier course of the same treatment. It aims to see if a second round can control the cancer again.
BordeauxAges 18 years+ - NCT05818683RecruitingPhase 1
Pasritamig plus other drugs for advanced prostate cancer
This Phase 1 study tests pasritamig (JNJ-78278343) combined with other prostate cancer treatments in people with advanced prostate cancer that has spread. It aims to find the safest dose and see whether the combinations can help slow the cancer.
Sarasota, FloridaAges 18 years+ - NCT06830850RecruitingPhase 1
Testing a new drug for metastatic prostate cancer
This trial tests a new drug, HRS-5041, for men whose prostate cancer has spread and stopped responding to hormone therapy. The goal is to see if the drug is safe and can help control the cancer.
Sydney, New South WalesAges 18 years+ - NCT05613738Recruiting
Test drug for advanced prostate cancer with high PSMA scans
This trial studies whether a PSMA-targeted treatment using 177Lu can help men with prostate cancer that has spread and is growing despite hormone treatment. It may help if your scan shows high PSMA in the tumor and your blood counts and organ function are adequate.
Beijing, Beijing MunicipalityAges 18–80 - NCT06193486RecruitingPhase 1
T-Cell Therapy for Advanced Prostate Cancer with Bone Spread
This trial tests a new type of immune cell therapy (gamma delta T cells) targeted at a marker on prostate cancer cells to see if it can shrink bone metastases in advanced, castration-resistant prostate cancer. It’s for men who have already tried chemotherapy and newer hormone therapies and whose cancer is getting worse.
Tampa, FloridaAges 18 years+ - NCT06702995RecruitingPhase 1/Phase 2
Study of XNW5004 plus enzalutamide for advanced prostate cancer
This trial tests a new drug, XNW5004, combined with enzalutamide for men with metastatic castration-resistant prostate cancer that has progressed despite other treatments. It aims to see if this combination can slow the cancer's growth.
Jinan, ShandongAges 18 years+ - NCT05116579Recruiting
Using blood DNA tests to track PARP inhibitor response
This trial uses a blood test (circulating tumor DNA) to see whether PARP inhibitors are working for certain men with advanced prostate cancer. It may help predict which treatment responses are likely and monitor changes over time.
Guangzhou, GuangdongAges 18–75 - NCT07192120RecruitingPhase 1/Phase 2
MHB048C for advanced solid tumors
This trial is testing a new medicine called MHB048C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06492122RecruitingPhase 1
Study of a radioactive drug for advanced prostate cancer
This trial tests a new radioactive treatment, [225Ac]Ac-FL-020, for men with metastatic castration-resistant prostate cancer (mCRPC) that has gotten worse despite other treatments. It's for those who have had at least one prior hormone therapy or chemotherapy.
Duarte, CaliforniaAges 18 years+
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic castration-resistant prostate cancer?
- Yes. Clin2 currently lists 220 recruiting metastatic castration-resistant prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic castration-resistant prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic castration-resistant prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castration-Resistant Prostate Cancer Patients
- Non-metastatic Castration-resistant Prostate Cancer
- Castration-resistant Prostate Cancer
- Metastatic Castration-Resistant Prostate Carcinoma
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Metastatic Prostate Cancer
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Castration-Resistant Prostate Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.